Larotrectinib Sulfate Patent Expiration

Larotrectinib Sulfate is Used for treating various solid tumors in pediatric patients exhibiting an NTRK gene fusion. It was first introduced by Bayer Healthcare Pharmaceuticals Inc in its drug Vitrakvi on Nov 26, 2018. 2 different companies have introduced drugs containing Larotrectinib Sulfate.


Larotrectinib Sulfate Patents

Given below is the list of patents protecting Larotrectinib Sulfate, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in Drug Patent Number Drug Patent Title Drug Patent Expiry Drug Owner
Vitrakvi US10005783 Method of treatment using substituted pyrazolo[1,5-a] pyrimidine compounds Oct 21, 2029 Bayer Healthcare
Vitrakvi US10005783 Method of treatment using substituted pyrazolo[1,5-a] pyrimidine compounds Oct 21, 2029 Bayer Hlthcare
Vitrakvi US10045991 Methods of treating pediatric cancers Apr 04, 2037 Bayer Healthcare
Vitrakvi US10047097 Method of treatment using substituted pyrazolo[1,5-a] pyrimidine compounds Oct 21, 2029 Bayer Healthcare
Vitrakvi US10047097 Method of treatment using substituted pyrazolo[1,5-a] pyrimidine compounds Oct 21, 2029 Bayer Hlthcare
Vitrakvi US10137127 Liquid formulations of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-A]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide Apr 04, 2037 Bayer Healthcare
Vitrakvi US10172861 Crystalline form of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-A]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate Nov 16, 2035 Bayer Healthcare
Vitrakvi US10172861 Crystalline form of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-A]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate Nov 16, 2035 Bayer Hlthcare
Vitrakvi US10285993 Crystalline form of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate Nov 16, 2035 Bayer Hlthcare
Vitrakvi US10668072 Liquid formulations of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide Apr 04, 2037 Bayer Healthcare
Vitrakvi US10774085 Method of treatment using substituted pyrazolo[1,5-A] pyrimidine compounds Oct 21, 2029 Bayer Healthcare
Vitrakvi US10774085 Method of treatment using substituted pyrazolo[1,5-A] pyrimidine compounds Oct 21, 2029 Bayer Hlthcare
Vitrakvi US10799505 Crystalline form of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-A]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate Aug 15, 2036 Bayer Healthcare
Vitrakvi US10799505 Crystalline form of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-A]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate Aug 15, 2036 Bayer Hlthcare
Vitrakvi US10813936 Crystalline form of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-YL)-pyrazolo[1,5-A]pyrimidin-3-YL)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate Nov 16, 2035 Bayer Hlthcare
Vitrakvi US11191766 Methods of treating pediatric cancers Apr 04, 2037 Bayer Healthcare
Vitrakvi US11484535 Liquid formulations of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a] pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide Apr 04, 2037 Bayer Healthcare
Vitrakvi US8513263 Substituted pyrazolo[1,5-a]pyrimidine compounds as Trk kinase inhibitors Dec 23, 2029 Bayer Healthcare
Vitrakvi US8513263 Substituted pyrazolo[1,5-a]pyrimidine compounds as Trk kinase inhibitors Dec 23, 2029 Bayer Hlthcare
Vitrakvi US8865698 Method of treatment using substituted pyrazolo[1,5-a]pyrimidine compounds Oct 21, 2029 Bayer Healthcare
Vitrakvi US8865698 Method of treatment using substituted pyrazolo[1,5-a]pyrimidine compounds Oct 21, 2029 Bayer Hlthcare
Vitrakvi US9127013 Method of treatment using substituted pyrazolo[1,5-a] pyrimidine compounds Oct 21, 2029 Bayer Healthcare
Vitrakvi US9127013 Method of treatment using substituted pyrazolo[1,5-a] pyrimidine compounds Oct 21, 2029 Bayer Hlthcare
Vitrakvi US9447104 Method of treatment using substituted pyrazolo[1,5-a]pyrimidine compounds Oct 21, 2029 Bayer Healthcare
Vitrakvi US9447104 Method of treatment using substituted pyrazolo[1,5-a]pyrimidine compounds Oct 21, 2029 Bayer Hlthcare
Vitrakvi US9676783 Method of treatment using substituted pyrazolo[1,5-A] pyrimidine compounds Oct 21, 2029 Bayer Healthcare
Vitrakvi US9676783 Method of treatment using substituted pyrazolo[1,5-A] pyrimidine compounds Oct 21, 2029 Bayer Hlthcare
Vitrakvi US9782414 Crystalline form of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-A]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate Nov 16, 2035 Bayer Healthcare
Vitrakvi US9782414 Crystalline form of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-A]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate Nov 16, 2035 Bayer Hlthcare


Coming Soon

Patent Strength Analyzer

Will this be useful for you?

YesNo

Thank you for your response 🥳